Product Center
Groundbreaking Ceremony for the Vaccine Industrialization Base Project of Ab&B Bio-Tech Co., Ltd. (JS)
- Categories:Industry news
- Author:
- Origin:
- Time of issue:2016-09-06
- Views:
(Summary description)On September 6, 2016, Ab&B Bio-Tech Co., Ltd. (JS) held the groundbreaking ceremony for its vaccine industrialization base project. The event was attended by Lu Chunyun, Standing Committee Member of Taizhou Municipal Party Committee and Secretary of the Pharmaceutical High-tech Zone Party Working Committee, along with Wu Yue, Director of the Pharmaceutical High-tech Zone Committee who presided over the ceremony.
Groundbreaking Ceremony for the Vaccine Industrialization Base Project of Ab&B Bio-Tech Co., Ltd. (JS)
(Summary description)On September 6, 2016, Ab&B Bio-Tech Co., Ltd. (JS) held the groundbreaking ceremony for its vaccine industrialization base project. The event was attended by Lu Chunyun, Standing Committee Member of Taizhou Municipal Party Committee and Secretary of the Pharmaceutical High-tech Zone Party Working Committee, along with Wu Yue, Director of the Pharmaceutical High-tech Zone Committee who presided over the ceremony.
- Categories:Industry news
- Author:
- Origin:
- Time of issue:2016-09-06 10:57
- Views:
On September 6, 2016, Ab&B Bio-Tech Co., Ltd. (JS) held the groundbreaking ceremony for its vaccine industrialization base project. The event was attended by Lu Chunyun, Standing Committee Member of Taizhou Municipal Party Committee and Secretary of the Pharmaceutical High-tech Zone Party Working Committee, along with Wu Yue, Director of the Pharmaceutical High-tech Zone Committee who presided over the ceremony. Other attendees included Wu Xiang, Deputy Secretary of the Medical Park Party Working Committee, and Zhou Jihong, Liu Lu, and Qin Xiaorui, Deputy Directors of the Medical Park Management Committee. An Youcai, Chairman and General Manager of Ab&B Bio-Tech Co., Ltd. (JS), delivered an address at the ceremony. Distinguished guests in attendance included Prof. Ma Xingyuan, Doctoral Advisor at East China University of Science and Technology; Mr. Li Zhonglin, Chairman of Shandong Weifang Jingying Medical Equipment Co., Ltd.; Mr. Zheng Xiaoyou, Vice President of Shanghai Tofflon Co., Ltd.; Mr. He Changbao, Sales Director of Chutian Technology; and Dr. Shen Mingjun, Chairman of Yangzhou Chaotiange Group. The ceremony drew over 300 participants representing various departments including construction, engineering, supervision, and the Medical Park.

Relevant information
-
How to choose a reliable influenza vaccine during the flu season? An evidence-based guide for subunit vaccines for all age groups
Influenza (commonly referred to as the flu) is an acute respiratory infectious disease caused by the influenza virus. Unlike the common cold, influenza is highly contagious and is characterized primarily by systemic symptoms. Elderly individuals, children under the age of 5, patients with chronic diseases, pregnant women, and individuals with compromised immune systems are all considered high-risk populations for severe influenza [1]. A study based on national influenza surveillance and cause-of-death surveillance data revealed that, on average, there are 88,000 excess deaths related to influenza-associated respiratory diseases annually across China [2]. The total economic burden on outpatient patients with influenza ranges from RMB 801 to RMB 1,320, while the total economic burden on hospitalized influenza patients ranges from RMB 9,832 to RMB 23,833 [1]. In the face of the significant challenge posed by influenza, influenza vaccination is currently recognized worldwide as the most cost-effective and effective means of preventing influenza [1]. - The leap in influenza vaccine technology: from split-virus vaccines to whole-population subunit vaccines – what are the key advancements in the third-generation vaccines? 08-19
- Exclusive Release | The influenza subunit vaccine "HRK-X® 3" makes its nationwide debut, ushering in a new chapter of scientific protection for all populations! 08-15
- High-dose influenza vaccines now available across the entire population – marking a new phase in influenza prevention and control with subunit vaccines 08-15
- Deepening Strategic Synergy to Jointly Strengthen Public Health Defense: Chongqing Center for Disease Control and Prevention (Chongqing Institute of Preventive Medicine) visited Ab&B Bio for a visit and exchange session. 08-06
Got a project? Contact us today !
At Ab&B Bio, our mission is to care for life and protect health by developing globally innovative vaccines.
Contact
E-mail:haixin.zhang@yitherbiotech.com
Add:No. 32, Xinglin Road, Medical High-tech Zone, Taizhou City
Quick view
Follow us